Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: A multicentre prospective study

Gut

Volumn 64, Issue 4, 2015, Pages 667-672

  Seto, Wai Kay ^a   Hui, Aric Josun ^b   Wong, Vincent Wai Sun ^c   Wong, Grace Lai Hung ^c   Liu, Kevin Sze Hang ^a   Lai, Ching Lung ^a   Yuen, Man Fung ^a   Chan, Henry Lik Yuen ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; HEPATITIS B SURFACE ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; BILE DUCT CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RETREATMENT; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; FEMALE; HEPATITIS B, CHRONIC; MIDDLE AGED; PREDICTIVE VALUE; TREATMENT WITHDRAWAL;

ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; WITHHOLDING TREATMENT;

EID: 84923060517     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307237     Document Type: Article

References (38)

1. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75.
2. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303.
3. Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537-47.
4. Zarski JP, Marcellin P, Leroy V, et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol 2006;45:355-60.
5. Fung J, Seto WK, Lai CL, et al. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. J Hepatol 2011;54:195-200.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
7. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
8. Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013;58:923-31.
9. Chan HL, Wang H, Niu J, et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007;12:345-53.
10. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
11. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.
12. Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-95.
13. Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629-36.e1.
14. Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011;34:344-52.
15. Liu F, Wang L, Li XY, et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011;26:456-60.
16. Jung YK, Yeon JE, Lee KG, et al. Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol 2011;17:261-7.
17. Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96.
18. Chan HL, Thompson A, Martinot-Peignoux M, et al . Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011;55:1121-31.
19. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-90.
20. Chan HL, Wong GL, Chim AM, et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantifi cation in hepatitis B e antigen-negative patients. Antivir Ther 2011;16:1249-57.
21. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6: 531-61.
22. Reijnders JG, Perquin MJ, Zhang N, et al . Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139:491-8.
23. Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009;104:1940-6.
24. Wong DK, Seto WK, Fung J, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 2013;11:1004-10 e1.
25. Wong DK, Yuen MF, Ngai VW, et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006;11:909-16.
26. Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004;101:638-40.
27. Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014;63:1325-32.
28. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet 2003;362:2089-94.
29. Ha NB, Ha NB, Garcia RT, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci 2011;56:2423-31.
30. Kamezaki H, Kanda T, Wu S, et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scand J Gastroenterol 2011;46:1111-17.
31. Lee GH, Inoue M, Toh JK, et al. Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance. Liver Int 2013;33:642-6.
32. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-44.
33. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010;52:1232-41.
34. Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013;59:709-16.
35. Wong GL, Chan HL, Lo AO, et al. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. Antivir Ther 2013;18:979-86.
36. Chan HL, Wong GL, Tse CH, et al. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011;204:408-14.
37. Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012;55:68-76.
38. Seto WK, Wong DK, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012;56:812-9.